Table 2.

Pharmacological characteristics of the main JAK-STAT pathway inhibitors available on the market

Drug	Inhibitory concentration (IC50)	Metabolism	Plasma half-life
Tofacitinib	JAK1: 2.9 nM	Hepatic CYP3A4 > CYP2C19	6 to 8h
	JAK2: 1.2 nM
	JAK3: 1.1 nM
	TYK2: 42 nM
Baricitinib	JAK1: 4.0 nM	Hepatic CYP3A4	10 to 13h
	JAK2: 6.6 nM
	JAK3: 787 nM
	TYK2: 61 nM
Ruxolitinib	JAK1: 6.4 nM	Hepatic CYP3A4	3 to 4h
	JAK2: 8.8 nM
	JAK3: 487.0 nM
	TYK2: 30.0 nM
Ritlecitinib	JAK1: 1.638 nM	Hepatic: CYP450; Serum: glutathione-S-transferase	2 to 3h
	JAK2: 1.507 nM
	JAK3: 0.3 nM
	TYK2: 3.779 nM
Abrocitinib	JAK1: 29 nM	Hepatic CYP2C19 > CYP2C9 > CYP3A4 > CYP2D6	3 to 5h
	JAK2: 803 nM
	JAK3: > 10.000 nM
	TYK2: 1.259 nM
Upadacitinib	JAK1: 14 nM	Hepatic CYP3A4 > CYP2D6	6 to 15h
	JAK2: 593 nM
	JAK3: 1.860 nM
	TYK2: 2.715 nM
Delgocitinib	JAK1: 2.8 nM	NA: topical use	NA: topical use
	JAK2: 2.6 nM
	JAK3: 13.0 nM
	TYK2: 58.0 nM